AMBU EXPANDS RECYCLING PROGRAM TO INCLUDE VIDEO LARYNGOSCOPE BLADES
29.10.2025 14:49:09 CET | Ambu A/S | Press release
Today, Ambu announces an extension of its Ambu® Recircle Program, now to include blades from the newly launched video laryngoscopy solution, Ambu® SureSight™ Connect.

Ambu has achieved another key milestone in its commitment to driving circular innovation in healthcare. The company’s pioneering endoscope recycling program – the Ambu® Recircle Program – will be expanded beyond endoscopes to also include blades from Ambu’s single-use video laryngoscope, Ambu® SureSight™ Connect.
Ambu’s video laryngoscope is part of the company’s Respiratory offering and is designed to support clinicians during intubation and upper airway procedures, for both routine and complex airway management procedures.
Ambu has initiated a feasibility study to determine how its Ambu® SureSight™ Connect blades can be seamlessly integrated into the recycling program alongside endoscopes. The company expects that customers will be able to recycle video laryngoscope blades in 2026.
“I am proud that we continue to lead the way with an innovative and practical approach to reducing the carbon footprint of the healthcare industry. The expansion of our Ambu® Recircle Program is a natural next step in expanding our recycling efforts across multiple solutions, reinforcing our commitment to our customers as a full-service partner.”
BRITT MEELBY JENSEN
Chief Executive Officer
REDUCING ENVIRONMENTAL IMPACT VIA CIRCULARITY AND RECYCLING
As the market leader in single-use endoscopy, Ambu recognizes the industry’s urgent need to address environmental challenges head-on. By advancing its commitment to circularity in the healthcare industry, Ambu is helping hospitals take meaningful climate action, while continuing to deliver high-quality patient care through advanced medical solutions.
Ambu launched its recycling program in June 2025, providing customers with an option to collect and recycle used Ambu endoscopes for new non-medical purposes. Currently, 28 hospitals across Germany, France, the United States, and the United Kingdom have joined the program.
The Ambu® Recircle Program is built on a circular approach, delivering a fully traceable and regulation-compliant recycling process for hospitals. From the moment an Ambu endoscope or video laryngoscope blade is collected after use, it undergoes a thorough process – including cleaning, shredding, and material recovery – to make sure useful materials are not thrown away or burned but reused as much as possible in new non-medical products.1
This end-to-end approach reflects Ambu’s commitment to reducing environmental impact across the entire product lifecycle, from raw material sourcing to post-use recovery, aimed to help both hospitals and Ambu lower their carbon footprints. This commitment is further supported by Ambu’s pioneering efforts integrating bioplastic materials2 into the handle of its fleet of single-use endoscopes, a milestone that Ambu achieved in 2024 as the first endoscopy company in the world.
|
ABOUT AMBU’S APPROACH TO CIRCULARITY |
|
Ambu is committed to embedding principles of the circular economy across the entire lifecycle of its solutions and packaging to support a more sustainable healthcare system. In a circular economy, the goal is to keep products, materials, and resources in use for as long as possible, extract the maximum value from them while in use, and then recover and regenerate products and materials at the end of their service life. |
1 With Ambu's recycling program, plastics from used Ambu endoscopes are collected, recycled, and repurposed into new, non-medical products – such as the chairs and tables featured on stage at our Capital Markets Day 2025 (view attachment).
2 The bioplastic material that Ambu is introducing in its fleet of single-use endoscopes is derived from a mix of bio-based second-generation feedstock and fossil-based feedstock, e.g., recycled food waste. Read more about Ambu’s use of bioplastics on the company’s website.
Keywords
Contacts
Tine Bjørn SchmidtDirector of Corporate Communications
Tel:+45 2264 0697tisc@ambu.comAnders HjortHead of Investor Relations
Tel:+45 2892 8881anhj@ambu.comDocuments
ABOUT AMBU
Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.
Subscribe to releases from Ambu A/S
Subscribe to all the latest releases from Ambu A/S by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Ambu A/S
AMBU EXTENDS RESPIRATORY OFFERING INTO PEDIATRIC AIRWAY PROCEDURES12.10.2026 12:39:52 CEST | Press release
Two bronchoscopes within the Ambu® aScope™ 5 Broncho portfolio have been cleared for pediatric use in the U.S. and Europe, extending Ambu’s Respiratory offering across both adult and pediatric patients.
AMBU APPOINTS BOARD OBSERVER, PLANS BOARD MEMBER NOMINATION28.9.2026 10:00:19 CEST | Press release
Current Grifols CEO and former Olympus executive, Nacho Abia, brings more than 20 years of leadership experience across global healthcare and endoscopy.
AMBU OBTAINS REGULATORY CLEARANCES FOR EXPANDED GI INDICATION25.9.2026 08:42:31 CEST | Press release
With an expanded indication for sigmoidoscopy procedures, Ambu® aScope™ Gastro and Ambu® aScope™ Gastro Large are the first single-use GI endoscopy solutions indicated for both upper and lower GI procedures, nearly doubling Ambu’s procedure reach in GI.
AMBU ACQUIRES TIMS MEDICAL TO ADVANCE ENDOINTELLIGENCE14.9.2026 15:00:00 CEST | Press release
The acquisition expands Ambu's endoscopy offering with established hospital integration and workflow technology and access to around 7,000 installations across U.S. hospitals, accelerating the Company's EndoIntelligence™ agenda.
AMBU EXPANDS NEUROLOGY PORTFOLIO IN NORTH AMERICA AND EUROPE20.8.2026 09:00:00 CEST | Press release
Ambu expands its neurology portfolio with an EEG solution that supports continued brain monitoring during MRI/CT scans, following FDA clearance and CE marking for Ambu® Neuroline™ Cup MRI/CT.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom